D. Machover
About
D. Machover is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine.
According to data from OpenAlex, D. Machover has authored 85 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 19 papers in Pathology and Forensic Medicine. Recurrent topics in D. Machover's work include Colorectal Cancer Treatments and Studies (26 papers), Cancer Treatment and Pharmacology (22 papers) and Gastric Cancer Management and Outcomes (13 papers). D. Machover is often cited by papers focused on Colorectal Cancer Treatments and Studies (26 papers), Cancer Treatment and Pharmacology (22 papers) and Gastric Cancer Management and Outcomes (13 papers). D. Machover collaborates with scholars based in France, United States and Spain. D. Machover's co-authors include Emma Goldschmidt, L Schwarzenberg, G. Metzger, Hans‐Joachim Schmoll, Göran Carlsson, F A Gibson, Arnaud Roth, Bengt Gustavsson, Nicholas J. Petrelli and J. L. Misset and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.
In The Last Decade
D. Machover
80 papers receiving 2.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| D. Machover France | 22 | 1.5k | 616 | 446 | 436 | 335 | 85 | 2.3k | ||
| A Mittelman United States | 26 | 1.3k 0.9× | 642 1.0× | 334 0.7× | 541 1.2× | 398 1.2× | 104 | 2.6k | ||
| J. L. Misset France | 27 | 2.1k 1.5× | 1.0k 1.7× | 438 1.0× | 433 1.0× | 452 1.3× | 63 | 3.0k | ||
| R. Voigtmann Germany | 16 | 988 0.7× | 514 0.8× | 279 0.6× | 594 1.4× | 164 0.5× | 38 | 1.8k | ||
| N. Renée France | 23 | 2.0k 1.4× | 622 1.0× | 483 1.1× | 752 1.7× | 243 0.7× | 65 | 2.6k | ||
| M C Etienne France | 27 | 2.1k 1.5× | 598 1.0× | 383 0.9× | 859 2.0× | 276 0.8× | 54 | 2.8k | ||
| Pierre Canal France | 34 | 1.9k 1.3× | 376 0.6× | 506 1.1× | 1.3k 3.1× | 302 0.9× | 138 | 3.4k | ||
| Muhammad Wasif Saif United States | 25 | 1.7k 1.2× | 639 1.0× | 246 0.6× | 562 1.3× | 475 1.4× | 129 | 2.7k | ||
| Bach Ardalan United States | 22 | 1.1k 0.8× | 453 0.7× | 247 0.6× | 601 1.4× | 311 0.9× | 105 | 1.9k | ||
| Stanislas Ropert France | 26 | 1.1k 0.7× | 757 1.2× | 202 0.5× | 729 1.7× | 192 0.6× | 67 | 2.5k | ||
| Ralph Levitt United States | 27 | 2.1k 1.4× | 892 1.4× | 407 0.9× | 670 1.5× | 682 2.0× | 67 | 3.6k |
Countries citing papers authored by D. Machover
Since
Specialization
Citations
This map shows the geographic impact of D. Machover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Machover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Machover more than expected).
Fields of papers citing papers by D. Machover
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by D. Machover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Machover. The network helps show where D. Machover may publish in the future.
Co-authorship network of co-authors of D. Machover
This figure shows the co-authorship network connecting the top 25 collaborators of D. Machover. A scholar is included among the top collaborators of D. Machover based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Machover. D. Machover is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kopečný, David, Antonia Boyer, Clément Pontoizeau, et al.. (2025). The methioninase from the alkalithermophile Thermobrachium celere possesses suitable properties for treatment of cancer. International Journal of Biological Macromolecules. 330(Pt 2). 147876–147876.
2.
Chen, Xingyu, et al.. (2023). PLP-Dependent Enzyme Methionine γ-Lyase: Insights into the Michaelis Complex from Molecular Dynamics and Free Energy Simulations. Biochemistry. 62(18). 2791–2801.
3.
Machover, D., Luigia Rossi, J. HAMELIN, et al.. (2019). Effects in Cancer Cells of the Recombinant L-Methionine Gamma-Lyase from Brevibacterium aurantiacum. Encapsulation in Human Erythrocytes for Sustained L-Methionine Elimination. Journal of Pharmacology and Experimental Therapeutics. 369(3). 489–502.
4.
Bouchahda, Mohamed, René Adam, Sylvie Giacchetti, et al.. (2009). Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer. 115(21). 4990–4999.
5.
Dubois, Josée, F. Rypens, Laurent Garel, et al.. (2007). Incidence of deep vein thrombosis related to peripherally inserted central catheters in children and adolescents. Canadian Medical Association Journal. 177(10). 1185–1190.
6.
Ulusakarya, Ayhan, et al.. (2006). Blepharitis Induced by Epidermal Growth Factor Receptor-Targeting Therapy. American Journal of Clinical Oncology. 29(5). 531–531.
7.
Tejpar, Sabine, Eric Van Cutsem, Érick Gamelin, et al.. (2004). Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). Journal of Clinical Oncology. 22(14_suppl). 3579–3579.
8.
Machover, D., Béatrice Delmas-Marsalet, Emma Goldschmidt, et al.. (2001). Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin’s lymphoma. Annals of Oncology. 12(10). 1439–1443.
9.
Tapiero, Haïm, K D Tew, Laurent Gaté, & D. Machover. (2001). Prevention of pathologies associated with oxidative stress and dietary intake deficiencies: folate deficiency and requirements. Biomedicine & Pharmacotherapy. 55(7). 381–390.
10.
Blazsek, I, et al.. (1999). Large scale recovery and characterization of stromal cell-associated primitive haemopoietic progenitor cells from filter-retained human bone marrow. Bone Marrow Transplantation. 23(7). 647–657.
11.
Machover, D.. (1997). A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer. 80(7). 1179–1187.
12.
Machover, D., et al.. (1993). Tandem high-dose (HD) chemotherapy (CT) with VM-26, ifosfamide (IFM), and carboplatin (CBDCA) with autologous bone marrow transplantation (ABMT) for patients with stage IIIC-IV ovarian cancer (OC). European Journal of Cancer. 29. S56–S56.
13.
Lotz, Jean‐Pierre, D. Machover, Benoı̂t Malassagne, et al.. (1991). Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.. Journal of Clinical Oncology. 9(10). 1860–1870.
14.
Hiesse, C, et al.. (1988). Membranous Nephropathy in a Bone Marrow Transplant Recipient. American Journal of Kidney Diseases. 11(2). 188–191.
15.
Mathé, G, J Gastiaburu, J.M. Vannetzel, et al.. (1986). Phase II trial of D-Trp-6-LH-RH in advanced breast cancer. European Journal of Cancer and Clinical Oncology. 22(6). 723–723.
16.
Jl, Misset, G Mathé, J Gastiaburu, et al.. (1982). [Treatment of leukemias and lymphomas with interferons: III. Trial treatment of meningeal localizations of acute leukemia and non-Hodgkin's lymphomas with beta interferon administered by the intrathecal route].. PubMed. 36(3). 167–70.
17.
Jl, Misset, J Gastiaburu, A Goutner, et al.. (1982). Treatment of lymphoid neoplasias with interferon. I. Human fibroblastic beta-interferon in malignant gammapathies. Phase II trial.. PubMed. 2(1-2). 63–6.
18.
Mathé, G, J. L. Misset, F. de Vassal, et al.. (1978). Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.. PubMed. 62(5). 805–9.
19.
Jl, Misset, Matthew J. Hayat, J. Gouveia, et al.. (1978). [Leukaemias and lymphomas treatment by vindesine. Result of a phase II trial in terms of remission induction (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 7(7). 525–8.
20.
Math�, G., M. Bayssas, J. Gouveia, et al.. (1978). Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. Cancer Chemotherapy and Pharmacology. 1(4). 259–62.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A Mittelman Breakdown of academic impact, for papers by J. L. Misset Breakdown of academic impact, for papers by R. Voigtmann Breakdown of academic impact, for papers by N. Renée Breakdown of academic impact, for papers by M C Etienne Breakdown of academic impact, for papers by Pierre Canal Breakdown of academic impact, for papers by Muhammad Wasif Saif Breakdown of academic impact, for papers by Bach Ardalan Breakdown of academic impact, for papers by Stanislas Ropert Breakdown of academic impact, for papers by Ralph Levitt